Skip to Content

Neumega (oprelvekin) Disease Interactions

There are 4 disease interactions with Neumega (oprelvekin):

Major

Oprelvekin (applies to Neumega) fluid retention

Major Potential Hazard, High plausibility. Applicable conditions: Hypokalemia, Congestive Heart Failure

Oprelvekin causes fluid retention that can result in peripheral edema, dyspnea on exertion, pulmonary edema, atrial arrhythmias, dilution decreases in hemoglobin and hematocrit and changes in serum electrolyte concentrations. Therapy with oprelvekin should be administered cautiously in patients adversely affected by fluid retention, such as patients with congestive heart failure. Clinical monitoring of fluid status and electrolyte levels is recommended.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (applies to Neumega) arrhythmias

Moderate Potential Hazard, High plausibility.

Transient artrial arrhythmias (fibrillation and flutter) have occurred in approximately 10% of patients receiving oprelvekin. Cardiac conditions, previous cardiotoxic chemotherapy, or advanced age are considered risk factors for development of oprelvekin- associated arrhythmias. Therapy with oprelvekin should be administered cautiously in patients with or predisposed to artrial arrhythmias.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (applies to Neumega) papilledema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Brain/Intracranial Tumor

Papilledema has been reported in 2% of patients receiving oprelvekin. Therapy with oprelvekin should be administered cautiously in patients with papilledema or CNS tumors as papilledema can be worsened or induced during therapy.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (applies to Neumega) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Oprelvekin is primarily eliminated by the kidneys and drug exposure was significantly increased in patients with severe renal impairment (CrCl <30 mL/min). The recommended dose in these patients is 50 mcg/kg once a day. No significant changes were observed in patients with mild or moderate impairment. Fluid retention associated with oprelvekin has not been studied in patients with renal impairment, but fluid balance should be carefully monitored in these patients.

Neumega (oprelvekin) drug interactions

There are 2 drug interactions with Neumega (oprelvekin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.